JP2023519851A5 - - Google Patents

Info

Publication number
JP2023519851A5
JP2023519851A5 JP2022558065A JP2022558065A JP2023519851A5 JP 2023519851 A5 JP2023519851 A5 JP 2023519851A5 JP 2022558065 A JP2022558065 A JP 2022558065A JP 2022558065 A JP2022558065 A JP 2022558065A JP 2023519851 A5 JP2023519851 A5 JP 2023519851A5
Authority
JP
Japan
Prior art keywords
sequence number
ctat
seq
bispecific antibody
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022558065A
Other languages
English (en)
Japanese (ja)
Other versions
JP7729833B2 (ja
JP2023519851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023655 external-priority patent/WO2021195067A1/en
Publication of JP2023519851A publication Critical patent/JP2023519851A/ja
Publication of JP2023519851A5 publication Critical patent/JP2023519851A5/ja
Priority to JP2025135194A priority Critical patent/JP2025161873A/ja
Application granted granted Critical
Publication of JP7729833B2 publication Critical patent/JP7729833B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022558065A 2020-03-23 2021-03-23 武装免疫細胞を産生する際に使用するための二重特異性抗体 Active JP7729833B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025135194A JP2025161873A (ja) 2020-03-23 2025-08-14 武装免疫細胞を産生する際に使用するための二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993080P 2020-03-23 2020-03-23
US62/993,080 2020-03-23
PCT/US2021/023655 WO2021195067A1 (en) 2020-03-23 2021-03-23 Bi-specific antibodies for use in producing armed immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025135194A Division JP2025161873A (ja) 2020-03-23 2025-08-14 武装免疫細胞を産生する際に使用するための二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2023519851A JP2023519851A (ja) 2023-05-15
JP2023519851A5 true JP2023519851A5 (cg-RX-API-DMAC10.html) 2024-04-02
JP7729833B2 JP7729833B2 (ja) 2025-08-26

Family

ID=77892613

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022558065A Active JP7729833B2 (ja) 2020-03-23 2021-03-23 武装免疫細胞を産生する際に使用するための二重特異性抗体
JP2025135194A Pending JP2025161873A (ja) 2020-03-23 2025-08-14 武装免疫細胞を産生する際に使用するための二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025135194A Pending JP2025161873A (ja) 2020-03-23 2025-08-14 武装免疫細胞を産生する際に使用するための二重特異性抗体

Country Status (8)

Country Link
US (1) US20240209084A1 (cg-RX-API-DMAC10.html)
EP (1) EP4126954A4 (cg-RX-API-DMAC10.html)
JP (2) JP7729833B2 (cg-RX-API-DMAC10.html)
CN (1) CN115551890A (cg-RX-API-DMAC10.html)
AU (1) AU2021244375A1 (cg-RX-API-DMAC10.html)
IL (1) IL296566A (cg-RX-API-DMAC10.html)
TW (1) TWI904147B (cg-RX-API-DMAC10.html)
WO (1) WO2021195067A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2023019179A1 (en) * 2021-08-11 2023-02-16 Cytoarm Co., Ltd. Process for producing armed immune cells
WO2023143478A1 (en) * 2022-01-27 2023-08-03 Crown Bioscience Inc. Novel anti-cd4 and anti-pd-l1 bispecific antibodies
CN118005806B (zh) * 2024-02-08 2026-01-30 北京市眼科研究所 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用
CN121248779A (zh) * 2024-06-25 2026-01-02 冕屹立生物技术(上海)有限公司 靶向人cd3分子的抗体及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US20130089554A1 (en) * 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
CN104640561A (zh) * 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
US9611325B2 (en) * 2014-07-21 2017-04-04 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody HER2xCD3
US9777073B2 (en) * 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
MX386342B (es) * 2014-07-25 2025-03-18 Memorial Sloan Kettering Cancer Center Móleculas de unión a her2 y cd3 biespecíficas.
ES2809455T3 (es) * 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
CN104829725A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd133×cd3的构建及应用
WO2017040195A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
PT3355913T (pt) * 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
EP3371311B1 (en) * 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3458481A4 (en) * 2016-05-18 2020-07-29 Mayo Foundation for Medical Education and Research TARGETING PD-L1 ON TUMOR CELLS
TW201825511A (zh) * 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CN110520523A (zh) * 2017-03-29 2019-11-29 台北医学大学 具抗原专一性的t细胞及其用途
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN111787951B (zh) * 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
US20220002398A1 (en) * 2018-06-07 2022-01-06 Oncoone Research & Development Gmbh ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
EP3849565A4 (en) * 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS

Similar Documents

Publication Publication Date Title
Felices et al. Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells
JP7461950B2 (ja) Cd3抗体およびその医薬用途
KR102777002B1 (ko) 항글리피칸-3 항체 및 이의 응용
Chen et al. Bispecific antibodies in cancer immunotherapy
CN107880128B (zh) 一种抗cd19的全人源抗体或抗体片段及其方法和应用
RU2019110835A (ru) Антитела к pd-1(cd279)
Omidfar et al. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody
US20160145339A1 (en) Construction and application of bispecific antibody HER2xCD3
JP2015527070A5 (cg-RX-API-DMAC10.html)
CN109055380B (zh) 一种通用型car-t细胞的制备方法
JP2022548796A5 (cg-RX-API-DMAC10.html)
FI3826667T3 (fi) Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi
CN103833852A (zh) 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
WO2017121758A1 (en) Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP7052149B2 (ja) 新型構造の抗vegf-抗pd1二重特異性抗体
CN104829725A (zh) 一种双特异性抗体cd133×cd3的构建及应用
TW201920272A (zh) 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用
Pfeifer Serrahima et al. Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies
IL320882A (en) And the uses of PSMA antibodies
CN104288765A (zh) 一种利用具有中和FLT3生物学活性的McAb应用于肿瘤的靶向治疗的新方法
JP2024540863A5 (cg-RX-API-DMAC10.html)
CN114258402B (zh) 抗cd123抗体、抗cd123嵌合抗原受体和抗cd123嵌合抗原受体t细胞
Huo et al. Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth